Jennifer Kayden Lee, EVP, Head of North America at RHYTHM PHARMACEUTICALS, INC. (RYTM), sold 115,982 shares at $65.68 ($7.7M) on 2024-11-11, disclosed to the SEC on 2024-11-13.
Scheduled sale ($7.7M) by EVP, Head of North America under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.68 | 38,051 | $2.5M | 32.5% |
| 2 | $65.68 | 38,051 | $2.5M | 32.5% |
| 3 | $66.95 | 17,540 | $1.2M | 15.3% |
| 4 | $67.56 | 11,070 | $748K | 9.7% |
| 5 | $67.56 | 11,070 | $748K | 9.7% |
| 6 | $68.43 | 200 |
| $14K |
| 0.2% |
| Total | $66.24 avg | 115,982 | $7.7M | 100% |
| Filing → |
| RYTM | SELL | 2025-02-14 | $240K | — | Filing → |
| RYTM | SELL | 2025-02-11 | $611K | — | Filing → |
| RYTM | SELL | 2025-02-07 | $359K | — | Filing → |